Compare STE & MEDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STE | MEDP |
|---|---|---|
| Founded | 1985 | 1992 |
| Country | United States | United States |
| Employees | 3700 | N/A |
| Industry | Industrial Specialties | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.3B | 17.2B |
| IPO Year | 2018 | 2016 |
| Metric | STE | MEDP |
|---|---|---|
| Price | $218.12 | $620.11 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 14 |
| Target Price | $263.13 | ★ $595.92 |
| AVG Volume (30 Days) | ★ 611.6K | 230.3K |
| Earning Date | 11-04-2026 | 10-21-2026 |
| Dividend Yield | ★ 1.29% | N/A |
| EPS Growth | ★ 27.90 | 20.98 |
| EPS | 7.93 | ★ 8.53 |
| Revenue | ★ $5,935,900,000.00 | N/A |
| Revenue This Year | $7.35 | $12.72 |
| Revenue Next Year | $6.36 | $6.33 |
| P/E Ratio | ★ $27.07 | $71.77 |
| Revenue Growth | ★ 8.73 | N/A |
| 52 Week Low | $195.14 | $373.00 |
| 52 Week High | $269.44 | $677.90 |
| Indicator | STE | MEDP |
|---|---|---|
| Relative Strength Index (RSI) | 59.21 | 56.15 |
| Support Level | $216.22 | $565.78 |
| Resistance Level | $220.39 | $632.08 |
| Average True Range (ATR) | 3.86 | 18.61 |
| MACD | 1.56 | -1.09 |
| Stochastic Oscillator | 87.21 | 58.18 |
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 20% from Applied Sterilization Technologies, or AST, and 10% from life sciences services after the divestment of its dental products business.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.